纳武单抗联合伊匹单抗治疗晚期肾细胞癌的早期进展分析
Analysis of Early Progression in Advanced Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab.
作者信息
Ito Naoki, Ueda Kosuke, Ohnishi Satoshi, Suekane Hiroki, Hiroshige Tasuku, Watanabe Kouta, Chikui Katsuaki, Uemura Keiichiro, Nishihara Kiyoaki, Nakiri Makoto, Suekane Shigetaka, Igawa Tsukasa
机构信息
Department of Urology, Kurume University School of Medicine, Kurume, Japan.
出版信息
Cancer Diagn Progn. 2025 May 3;5(3):344-352. doi: 10.21873/cdp.10446. eCollection 2025 May-Jun.
BACKGROUND/AIM: In the CheckMate 214 trial, approximately 40% of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab plus ipilimumab (NIVO + IPI) achieved long-term survival and a durable response to treatment. However, about 20% of patients experienced early disease progression (EDP). This retrospective study aimed to identify predictive factors for EDP among patients with aRCC treated with NIVO + IPI.
PATIENTS AND METHODS
We retrospectively analyzed clinical information from patients with aRCC, 19 patients in the EDP group and 40 patients in the control disease group, all of whom were treated with NIVO + IPI at Kurume University Hospital between September 2018 and February 2024.
RESULTS
The EDP group exhibited significantly worse progression-free survival and overall survival compared to the control disease group. Multivariate analyses revealed that a performance states (PS) ≥2 (p=0.0312) and the presence of bone metastases (p=0.0374) were independent predictors of EDP.
CONCLUSION
Treatment with NIVO + IPI in patients with aRCC who have a poor PS or bone metastases may be linked to a high risk of EDP.
背景/目的：在CheckMate 214试验中，接受纳武单抗加伊匹木单抗（NIVO + IPI）治疗的晚期肾细胞癌（aRCC）患者中，约40%实现了长期生存且对治疗有持久反应。然而，约20%的患者出现了早期疾病进展（EDP）。这项回顾性研究旨在确定接受NIVO + IPI治疗的aRCC患者中EDP的预测因素。
患者与方法
我们回顾性分析了aRCC患者的临床信息，EDP组19例患者，疾病对照组40例患者，所有患者均于2018年9月至2024年2月在久留米大学医院接受NIVO + IPI治疗。
结果
与疾病对照组相比，EDP组的无进展生存期和总生存期显著更差。多因素分析显示，体能状态（PS）≥2（p = 0.0312）和存在骨转移（p = 0.0374）是EDP的独立预测因素。
结论
PS较差或有骨转移的aRCC患者接受NIVO + IPI治疗可能与EDP的高风险相关。
Zotero 插件